Neurocrine Biosciences (NBIX) Tops Q2 EPS by 127c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $158.35 +0.35%
EPS Growth %: -12.4%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
VIVO, PMCB, PLCE, More
EPS Growth %: -12.4%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $2.85, $1.27 better than the analyst estimate of $1.58. Revenue for the quarter came in at $959 million versus the consensus estimate of $877.34 million.
GUIDANCE:
Neurocrine Biosciences sees FY2026 revenue of $2.82-2.87 billion, versus the consensus of $3.79 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Smith & Wesson Brands (SWBI) Tops Q1 EPS by 13c
- Intel (INTC) PT Lowered to $92 at Mizuho
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
